Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA Buys Bangalore 'Omics Firm

NEW YORK (GenomeWeb News) – Merck KGaA today said that it has bought Bangalore Genei (India) Private (BGIP), which makes and sells 'omics tools, through its Merck Specialties subsidiary for an undisclosed sum.

Merck acquired the Bangalore-based firm, which specializes in making and selling genomics and proteomics research products, from the Sanmar Group. The company employs over 100 people and had revenues of around INR202 million ($4.4 million) in fiscal year 2009.

"BGIP's leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base," Christina Shasserre, global head of Merck's bioscience business, said in a statement. "BGIP's product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India."

Financial terms of the agreement were not released.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.